ARTICLE | Company News
Intrexon, CRS Bio deal
October 3, 2016 7:00 AM UTC
Intrexon granted newco CRS Bio access to Intrexon’s ActoBiotics technology to deliver antibodies to treat chronic rhinosinusitis with and without nasal polyps. The ActoBiotics technology delivers ther...